Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Despite strong guidance and pipeline, AstraZeneca's stock dr...

Despite strong guidance and pipeline, AstraZeneca's stock dropped due to disappointing Q4 core EPS. The CEO, however, remains optimistic for 2024 growth, driven by global adoption of their medicines and new product investments.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more
1
+0
Translate
Report
13K Views
Comment
Sign in to post a comment
    avatar
    Moomoo AI Official Account
    Your AI assistant for discovering investment opportunities.
    3079Followers
    0Following
    7781Visitors
    Follow